Loading
Life sciences · Journal article
Cell Death Discovery · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Colorectal cancer (CRC) metastasis presents a formidable clinical challenge, particularly for microsatellite stability (MSS) subtypes that show limited response to current targeted therapies and immunotherapies. While transforming growth factor beta (TGF-β) signaling is recognized as an inducer of the mesenchymal transition program, including epithelial–mesenchymal transition (EMT) and extracellular matrix (ECM) remodeling in metastatic progression, the upstream molecular mechanisms controlling TGF-β pathway activation in metastasis remain unclear. Here, we identified sushi repeat-containing protein X-linked 2 (SRPX2) as a novel metastasis driver that orchestrates TGF-β signaling through an unexpected molecular mechanism. Our multi-omics analysis of metastatic CRC datasets revealed SRPX2 as the top candidate gene associated with aggressive progression and immunotherapy resistance. Mechanistically, SRPX2 binds to and stabilizes TGFBR2, activating the TGF-β signaling pathway that promotes EMT/ECM reprogramming. We further demonstrated that SRPX2 ablation suppresses liver metastasis and enhances tumor sensitivity to immune checkpoint inhibitors, accompanied by reduced mesenchymal abundance. These findings establish SRPX2 as a crucial molecular switch controlling TGF-β pathway activation in CRC metastasis and reveal its dual role in promoting stromal remodeling and immune evasion. Our work provides a compelling rationale for targeting the SRPX2/TGF-β axis as a novel therapeutic strategy for aggressive CRC subsets.